



ASX Announcement | 30 September 2026
AdAlta Limited (ASX:1AD)

NOTIFICATION OF DATE OF 2026 AGM

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cellular immunotherapies for solid cancers, advises that the Company’s Annual General Meeting (AGM) will be held on Wednesday, 25 November 2026 at 11:00am AEDT at Piper Alderman, Level 23, 459 Collins Street, Melbourne VIC 3000.

Following formalities, AdAlta’s CEO and Managing Director, Dr Tim Oldham will provide a business update to Shareholders.

Further to Listing Rules 3.13.1 and 13.3 and the Company Constitution, nominations for elections of directors at the AGM must be received not less than 35 business days before the meeting, being no later than Tuesday 6 October 2026.

Further details, will be provided in the forthcoming Notice of Meeting.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

- Visit: www.automicgroup.com.au
- E-mail: hello@automic.com.au
- Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

This ASX announcement has been authorised for release by the CEO & Managing Director of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 403 446 665
E: ir@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model

delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's other assets include first in class fusion protein, AD-214, that takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis and WD-34, a novel pan-strain inhibitor of malaria, Babesia and Toxoplasma parasites. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. WD-34 is seeking grant funding to optimize the molecule format to enable single dose seasonal prophylaxis.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)